eligibility_summary
Eligibility: adults ≥18 with advanced thymoma/thymic carcinoma after ≥1 prior systemic therapy, measurable disease (RECIST 1.1), tumor tissue available or waiver, ECOG 0–2, adequate marrow/organ function (ANC≥1500, platelets≥100k, Hgb≥8, liver/renal/coag within limits). Controlled HIV/HBV/HCV allowed, other non-interfering cancers OK, contraception required. Exclude: investigator concerns, pregnancy/breastfeeding, symptomatic brain mets needing steroids, concurrent anticancer therapy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase II, single-arm study in advanced thymoma/thymic carcinoma after ≥1 prior therapy. Intervention: Sacituzumab govitecan-hziy, an antibody–drug conjugate (ADC). Drug type/mechanism: Humanized anti–Trop-2 monoclonal antibody linked to SN-38 (active metabolite of irinotecan), a topoisomerase I inhibitor. The ADC binds Trop-2 on tumor cells, is internalized, and releases SN-38 to inhibit Topo I, causing DNA damage and apoptosis, with potential bystander effect. Targets: Trop-2–expressing thymic epithelial tumor cells, pathways: Trop-2 surface antigen and DNA replication/repair via Topo I.